Literature DB >> 32651251

Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features.

Sergio Muñiz-Castrillo1,2, Bastien Joubert1,2, Mad-Hélénie Elsensohn3,4, Anne-Laurie Pinto1,2, Margaux Saint-Martin1,2, Alberto Vogrig1,2, Géraldine Picard1,2, Véronique Rogemond1,2, Valérie Dubois5, Ryad Tamouza6,7, Delphine Maucort-Boulch3,4, Jérôme Honnorat8,2.   

Abstract

OBJECTIVE: Antibodies against contactin-associated protein-like 2 (CASPR2-Abs) have been described in acquired neuromyotonia, limbic encephalitis (LE) and Morvan syndrome (MoS). However, it is unknown whether these constitute one sole spectrum of diseases with the same immunopathogenesis or three distinct entities with different mechanisms.
METHODS: A cluster analysis of neurological symptoms was performed in a retrospective cohort of 56 CASPR2-Abs patients. In parallel, immunological features and human leucocyte antigen (HLA) were studied.
RESULTS: Cluster analysis distinguished patients with predominant limbic symptoms (n=29/56) from those with peripheral nerve hyperexcitability (PNH; n=27/56). In the limbic-prominent group, limbic features were either isolated (LE/-; 18/56, 32.1%), or combined with extralimbic symptoms (LE/+; 11/56, 19.6%). Those with PNH were separated in one group with severe PNH and extralimbic involvement (PNH/+; 16/56, 28.6%), resembling historical MoS descriptions; and one group with milder and usually isolated PNH (PNH/-; 11/56, 19.6%). LE/- and LE/+ patients shared immunogenetic characteristics demonstrating a homogeneous entity. HLA-DRB1*11:01 was carried more frequently than in healthy controls only by patients with LE (94.1% vs 18.3%; p=1.3×10-10). Patients with LE also had serum titres (median 1:40 960) and rates of cerebrospinal fluid positivity (93.1%) higher than the other groups (p<0.05). Conversely, DRB1*11:01 association was absent in PNH/+ patients, but only they had malignant thymoma (87.5%), serum antibodies against leucine-rich glioma-inactivated 1 protein (66.7%) and against netrin-1 receptor deleted in colorectal carcinoma (53.8%), and myasthenia gravis (50.0%).
INTERPRETATION: Symptoms' distribution supports specific clinical phenotypes without overlap between LE and MoS. The distinct immunogenetic characteristics shared by all patients with LE and the particular oncological and autoimmune associations of MoS suggest two very different aetiopathogenesis. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  CASPR2; HLA; Morvan syndrome; limbic encephalitis; neuromyotonia

Mesh:

Substances:

Year:  2020        PMID: 32651251     DOI: 10.1136/jnnp-2020-323226

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  13 in total

1.  Familial autoimmunity in neurological patients with GAD65 antibodies: an interview-based study.

Authors:  Sergio Muñiz-Castrillo; Alberto Vogrig; Clémentine Montagnac; Bastien Joubert; Marie Benaiteau; Olivier Casez; Hugo Chaumont; Lucie Hopes; Hélène-Marie Lanoiselée; Vincent Navarro; Benjamin Thomas; Renata Ursu; David Gonçalves; Nicole Fabien; François Ducray; Cécile Julier; Jérôme Honnorat
Journal:  J Neurol       Date:  2021-02-05       Impact factor: 4.849

Review 2.  Novelties in Autoimmune and Paraneoplastic Cerebellar Ataxias: Twenty Years of Progresses.

Authors:  Sergio Muñiz-Castrillo; Alberto Vogrig; Nicolás Lundahl Ciano-Petersen; Macarena Villagrán-García; Bastien Joubert; Jérôme Honnorat
Journal:  Cerebellum       Date:  2022-01-12       Impact factor: 3.648

3.  Distinctive clinical presentation and pathogenic specificities of anti-AK5 encephalitis.

Authors:  Sergio Muñiz-Castrillo; Julien Jacques Hedou; Aditya Ambati; David Jones; Alberto Vogrig; Anne-Laurie Pinto; Marie Benaiteau; Thomas de Broucker; Laura Fechtenbaum; Pierre Labauge; Matthew Murnane; Claire Nocon; Irina Taifas; Clément Vialatte de Pémille; Dimitri Psimaras; Bastien Joubert; Valérie Dubois; Valentin Wucher; Virginie Desestret; Emmanuel Mignot; Jérôme Honnorat
Journal:  Brain       Date:  2021-10-22       Impact factor: 13.501

4.  Signaling pathways of genetic variants and miRNAs in the pathogenesis of myasthenia gravis.

Authors:  Kai Qian; Jia-Xin Xu; Yi Deng; Hao Peng; Jun Peng; Chun-Mei Ou; Zu Liu; Li-Hong Jiang; Yong-Hang Tai
Journal:  Gland Surg       Date:  2020-12

5.  Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes.

Authors:  Francesc Graus; Alberto Vogrig; Sergio Muñiz-Castrillo; Jean-Christophe G Antoine; Virginie Desestret; Divyanshu Dubey; Bruno Giometto; Sarosh R Irani; Bastien Joubert; Frank Leypoldt; Andrew McKeon; Harald Prüss; Dimitri Psimaras; Laure Thomas; Maarten J Titulaer; Christian A Vedeler; Jan J Verschuuren; Josep Dalmau; Jerome Honnorat
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-05-18

Review 6.  Fundamental Mechanisms of Autoantibody-Induced Impairments on Ion Channels and Synapses in Immune-Mediated Cerebellar Ataxias.

Authors:  Hiroshi Mitoma; Jerome Honnorat; Kazuhiko Yamaguchi; Mario Manto
Journal:  Int J Mol Sci       Date:  2020-07-13       Impact factor: 5.923

7.  Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis.

Authors:  Sergio Muñiz-Castrillo; Julie Haesebaert; Laure Thomas; Alberto Vogrig; Anne-Laurie Pinto; Géraldine Picard; Charlotte Blanc; Le-Duy Do; Bastien Joubert; Giulia Berzero; Dimitri Psimaras; Agusti Alentorn; Véronique Rogemond; Valérie Dubois; Aditya Ambati; Ryad Tamouza; Emmanuel Mignot; Jérôme Honnorat
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-03-05

Review 8.  Current Status of Biomarkers in Anti-N-Methyl-D-Aspartate Receptor Encephalitis.

Authors:  Nicolás Lundahl Ciano-Petersen; Pablo Cabezudo-García; Sergio Muñiz-Castrillo; Jérôme Honnorat; Pedro Jesús Serrano-Castro; Begoña Oliver-Martos
Journal:  Int J Mol Sci       Date:  2021-12-04       Impact factor: 5.923

Review 9.  Short- and Long-Lived Autoantibody-Secreting Cells in Autoimmune Neurological Disorders.

Authors:  C Zografou; A G Vakrakou; P Stathopoulos
Journal:  Front Immunol       Date:  2021-06-17       Impact factor: 7.561

10.  Combining clinical and molecular heterogeneity within CASPR2-antibody mediated diseases: towards the underlying disease biology.

Authors:  Sophie Binks; Sarosh R Irani
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-07-10       Impact factor: 13.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.